Last updated on: 01/11/2013
1. Contact details
This data source is maintained by the following centre registered in the ENCePP inventory of research centres: Drugs and Pregnancy
Name of data sourceThe Finnish Drugs and Pregnancy Database
Name under which the data source should be displayed in the inventory (e.g short name if one exists)Drugs and Pregnancy Finland
Name of organisation
1) Department/research groupDrugs and Pregnancy -research
2) Organisation/affiliationNational Institute for Health and Welfare, THL
Administrative Contact
Title Dr
Last name Lahesmaa-Korpinen
First name Anna-Maria
Address line 1P.O. BOX 30
Address line 2
Address line 3
CityHelsinki
Postcode00271
CountryFinland
Scientific Contact
Title Dr
Last name Lahesmaa-Korpinen
First name Anna-Maria
Address line 1P.O. BOX 30
Address line 2
Address line 3
CityHelsinki
Postcode00271
CountryFinland
2. Description/category
Administrative database, e.g. claims database
Case-control surveillance database
Retrospective database of mothers and babies in Finland. Includes information on stillbirths and early deaths.
3.1 Coverage of licensed medicinal products
Licensed Medicinal Product
Comments
Community / general practice data
Prescription drug database
3.2 ATC code (5th level)
Yes
3.3 Other product dictionaries
No
3.4 Recording of indication for use
Yes
Is a coding dictionary being used?
No
4. Coverage of events
Event
Dictionary
Dictionary details
Symptoms/signs
No
Diagnosis in primary care
No
Specialist diagnosis
No
Laboratory values
No
Death
No
Procedures
No
Teratogenic events
No
5. Year of establishment
2003
6. Geographical origin of data
EEA/EFTA countries
Finland
7. Demographical extent of data collection
Nation-wide
8. Age groups
17 years and under [Paediatrics]
preterm newborn infants
term newborn infants (0 to 27 days)
infants and toddlers (28 days to 23 months)
18 to 45 years
9. Size of the source/catchment population
120,000
10 a. Total (cumulative) number of persons with actual data
2,000,000
10 b. Number of persons with active data collection in past calendar year
120,000
11. Possibility to obtain additional information on the patient
a) Clinical information from treating physician?
No
b) Questionnaire data from the patient?
No
c) Genetic information or samples?
No
12. Possibility of links to other sources of data
Yes :
Special permissions from authorities needed.
13. Written policy governing data access
Yes
14. Committee to evaluate requests for data access
Yes
15. Charge/fee for data access
Yes
Special arrangements for academic purposes:
Yes
16. Selected publications of the last 5 calendar years using data from this data source
ReferenceLink to web-publication
Artama M, Gissler M, Malm H, Ritvanen A; Drug and Pregnancy Group. Effects of
maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health
in offspring: nationwide, retrospective cohort study in Finland. Drug Saf. 2013
May;36(5):359-69.http://www.ncbi.nlm.nih.gov/pubmed/23615755
Stephansson O, Kieler H, Haglund B, Artama M, et al. Selective serotonin reuptake
inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA.
2013 Jan 2;309(1):48-54.http://www.ncbi.nlm.nih.gov/pubmed/23280224
Kieler H, Artama M, Engeland A, Ericsson O, et al. Selective
serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary
hypertension in the newborn: population based cohort study from the five Nordic
countries. BMJ. 2012 Jan 12;344:d8012.http://www.ncbi.nlm.nih.gov/pubmed/22240235
Artama M, Gissler M, Malm H, Ritvanen A. Nationwide
register-based surveillance system on drugs and pregnancy in Finland 1996-2006. Pharmacoepidemiol
Drug Saf. 2011 Jul;20(7):729-38.http://www.ncbi.nlm.nih.gov/pubmed/21626607
